Bi-specific T cell engagers (BiTEs) activate T cells through CD3 and target activated T cells to tumor-expressed antigens. BiTEs have shown therapeutic efficacy in patients with liquid …

Mar 15, 2025 · CD3 bispecific antibodies are a powerful tool in cancer immunotherapy, designed to engage T cells for targeted tumor destruction. Unlike traditional monoclonal antibodies, …

One of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor specific molecule. [2][3] A BiTE linking a T cell to a tumor cell. Like other bispecific antibodies, …

Apr 30, 2021 · Bispecific T-cell engager (BiTE) molecules exert antitumor activity by binding one arm to CD3 on cytotoxic T cells and the other arm to a tumor-associated antigen.

Blinatumomab is a 55 kDa-fusion protein comprised of two single-chain antibodies to CD19 and CD3, recombinantly joined by a flexible, non-glycosylated five-amino acid non-immunogenic …

Nov 28, 2018 · Here we show that a BiTE antibody construct directed against HCMV glycoprotein B (gB) and CD3 efficiently triggers T cells to secrete IFN-γ and TNF upon co-culture with …

Feb 10, 2025 · One of the most promising cancer immunotherapies is based on bi-specific T-cell engagers (BiTEs) that simultaneously bind with one arm to a tumor-associated antigen on …

Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 …

Nov 14, 2023 · One arm of a BiTE binds to a protein on the cancer cell, while the other arm binds to the CD3 protein on T cells. The T cell found the cancer cell—now what? To avoid …

Mar 15, 2024 · Anti-CD19/CD3 bispecific T-cell engagers (CD19BiTE) have shown promising efficacy in patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) …